InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.490 -0.05 (-9.26%)+
Announcement
Release
12 Aug 2026 8:36AM
Price at Release
$0.540
Full Release
download
Summary
Alterity Therapeutics Limited announced the granting of a new U.S. composition of matter patent for ATH434, their lead clinical asset. This patent provides protection for a crystalline structure of ATH434 mesylate and extends its commercial life until at least 2045, significantly enhancing the drug's strategic value and long-term commercial potential. ATH434 is an oral agent designed to address neurodegenerative diseases such as Multiple System Atrophy (MSA) and Parkinson's disease by reducing iron accumulation and inhibiting abnormal protein aggregation in the brain. Positive results from Phase 2 clinical trials have demonstrated its efficacy and safety in treating MSA. The new patent also supports future development opportunities for ATH434 in other major neurodegenerative disorders. Alterity is preparing to initiate Phase 3 trial activities by the end of 2026, with ATH434 having already received Fast Track and Orphan Drug Designations from the U.S. FDA and the European Commission.
Key Points
  • Alterity Therapeutics has been granted a new U.S. patent for ATH434 extending protection to at least 2045.
  • ATH434 is designed to treat neurodegenerative diseases like Multiple System Atrophy (MSA) and Parkinson's.
  • The patent covers a crystalline form of ATH434 mesylate and methods for treating neurological conditions.
  • ATH434 has shown positive results in Phase 2 clinical trials for MSA.
  • The patent enhances the strategic value of ATH434, supporting potential partnerships.
  • Alterity plans to initiate Phase 3 trials for ATH434 in MSA by the end of 2026.
  • ATH434 has been granted Fast Track and Orphan Drug Designations by the FDA and European Commission.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.